{"id":3168,"date":"2026-04-16T12:03:36","date_gmt":"2026-04-16T12:03:36","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/technical-note\/intracerebral-microdialysis\/"},"modified":"2026-04-16T14:56:31","modified_gmt":"2026-04-16T14:56:31","slug":"intracerebral-microdialysis","status":"publish","type":"technical-note","link":"https:\/\/www.sygnaturediscovery.com\/fr\/technical-note\/intracerebral-microdialysis\/","title":{"rendered":"in vivo Neurochemistry"},"content":{"rendered":"\n

Sygnature Discovery is a leading provider of intracerebral microdialysis services in rats and mice using passive methodologies and has just introduced the use of cerebral open flow microperfusion technology as part of its neurochemistry offering. Our dedicated team of experts have been conducting microdialysis studies for more than 20 years and can design bespoke studies to meet clients\u2019 precise needs.<\/p>\n\n\n\n

Microdialysis<\/h2>\n\n\n\n

Microdialysis <\/strong>is a technique which studies the effects of drugs on free concentrations of neurotransmitters and neuromodulators in different brain regions of freely moving or anaesthetized rodents. Typically, these studies evaluate the mode of action and\/or efficacy of candidate compounds with potential for the treatment of CNS and metabolic disorders by characterizing their effects on neurochemistry in normal rodents and\/or rodent models of a disease state.<\/p>\n\n\n\n

Cerebral Open Flow Microperfusion (cOFM)<\/h2>\n\n\n\n

cOFM<\/strong> is an evolution of microdialysis that replaces the membrane at the tip of the probe with an open matrix, allowing direct sampling of the interstitial fluid as opposed to the passive diffusion method utilized by standard microdialysis. This in turn allows for greater recovery of analytes. The materials the cOFM probes are made from are designed to be as low bind as possible, allowing better recovery of lipophilic compounds and endogenous analytes. Their materials are also more inert than the membranes of traditional microdialysis probes meaning tissue reactivity to cOFM probes is minimal, significantly reducing glial scarring associated with long term implantation. This lends them to being ideal for PK\/PD assessments as the disruption to the blood-brain barrier from implantation can be left to heal prior to sampling (recommended 2\u2011week recovery period for complete healing of BBB) leading to better compartmentalization between ISF, CSF and plasma.<\/p>\n\n\n\n

\"Four<\/figure>\n\n\n\n

Results are adjusted means; n=6 (CMA) n=5-6 (cOFM). SEMs are calculated from the residuals of the statistical model. Comparisons to vehicle for each probe are by the multiple t test. Significant differences vs vehicle: *p<0.05, **p<0.01, ***p<0.001.\u00a0 Comparisons to the CMA probe (\u2020p<0.05, \u2020\u2020p<0.01, \u2020\u2020\u2020p<0.001) are by a mixed linear model.<\/p>\n\n\n\n

High-Sensitivity Neurochemical Analysis<\/h2>\n\n\n\n

Our experts use high sensitivity UHPLC and HPLC with electrochemical detection (ALEXYS\u2122) or mass spectrometry (Thermo Scientific TSQ Altis) to measure:<\/strong><\/h3>\n\n\n\n